Product Description
Mechanisms of Action: ATP-sensitive potassium channel Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Danish Headache Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ILIM | N/A |
Recruiting |
Migraine with Aura|Headache Disorders|Migraine Disorders|Migraine without Aura |
2025-01-01 |
|
SLIM | N/A |
Recruiting |
Headache Disorders|Migraine with Aura|Migraine Disorders|Migraine without Aura |
2025-01-01 |
|
Glibenclamide H-18052188 | N/A |
Unknown status |
Headache |
2023-08-30 |
|
H-21028500 | N/A |
Recruiting |
Epilepsy|Headache Disorders|Migraine Disorders|Migraine with Aura|Migraine without Aura |
2023-07-31 |